BioSpace News Archive

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter 2022 financial results on Tuesday, March 28, 2023.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).

Culture Biosciences announced that it is increasing its focus on upstream bioprocess development of new therapeutics.

EMulate Therapeutics, Inc. today announced the addition of Donna Morgan Murray, Ph.D. to the Company’s board of directors.

DarioHealth Corp. (Nasdaq: DRIO)(the “Company” or “Dario”) announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models.

Vesigen Therapeutics, Inc. is pleased to announce receipt of a FARA General Research Grant. Vesigen will evaluate its proprietary technology to deliver CRISPR-Cas genome editing complexes as a non-viral disease-modifying strategy for patients diagnosed with the neurodegenerative disease Friedreich’s Ataxia (FA).

BioMarin Pharmaceutical Inc. will present updated data demonstrating the long-term benefit of treatment with VOXZOGO® (vosoritide) and new observational data on disease burden in children with achondroplasia.

Edgewise Therapeutics, Inc. today announced that the company will present on EDG-5506 at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference.

Florence Healthcare and IQVIA have entered a multiyear collaboration to ensure research sites participating in IQVIA studies have access to site enablement technology.

Catamaran Bio Inc. and OmniaBio Inc. today announced their partnership to develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.